Compare CELU & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CELU | BDSX |
|---|---|---|
| Founded | 2016 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.7M | 53.0M |
| IPO Year | N/A | 2020 |
| Metric | CELU | BDSX |
|---|---|---|
| Price | $1.96 | $7.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $6.00 | ★ $32.50 |
| AVG Volume (30 Days) | ★ 65.1K | 62.9K |
| Earning Date | 11-14-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $40,578,000.00 | ★ $80,173,000.00 |
| Revenue This Year | N/A | $20.75 |
| Revenue Next Year | $76.00 | $25.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 22.29 |
| 52 Week Low | $1.00 | $3.44 |
| 52 Week High | $4.35 | $32.20 |
| Indicator | CELU | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 55.41 | 51.69 |
| Support Level | $1.62 | $7.68 |
| Resistance Level | $2.18 | $8.17 |
| Average True Range (ATR) | 0.14 | 0.66 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 60.76 | 55.68 |
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.